NICOLE', Stefano
NICOLE', Stefano
Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials
2018-01-01 Nicole', Stefano; Lanzafame, M; Cucchetto, Giulia; Rigo, F; Lattuada, E; Concia, E
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient
2017-01-01 Lanzafame, Massimiliano; Lattuada, Emanuela; Nicole', Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro
Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up
2017-01-01 Lanzafame, Massimiliano; Nicole', Stefano; Gibellini, Davide; Lattuada, Emanuela; Cucchetto, Giulia; Rigo, Fabio; Diani, Erica; Concia, Ercole; Vento, Sandro
Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients
2017-01-01 Rigo, F; Cucchetto, G; Lanzafame, Massimiliano; Nicolè, S; Lattuada, Emanuela; Concia, Ercole; Vento, Sandro
Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients
2019-01-01 Nicolè, Stefano; Lanzafame, Massimiliano; Lattuada, Emanuela; Luise, Dora; Vecchi, Marta; Tacconelli, Evelina; Vento, Sandro
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study
2019-01-01 Rizzardo, Sebastiano; Lanzafame, Massimiliano; Lattuada, Emanuela; Bragantini, Damiano; Nicolè, Stefano; Calza, Leonardo; Tacconelli, Evelina
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir
2018-01-01 Lanzafame, M; Nicole, S; Rizzardo, S; Piacentini, D; Chiesi, S; Lattuada, E; Diani, E; Carelli, M; Vento, S; Gibellini, D
Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings
2017-01-01 Cucchetto, Giulia; Lanzafame, Massimiliano; Nicolè, Stefano; Lattuada, Emanuela; Calza, Leonardo; Concia, Ercole
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients
2015-01-01 Lanzafame, Massimiliano; Lattuada, Emanuela; Rigo, Fabio; Nicole, Stefano; Cucchetto, Giulia; Vento, Sandro
Successful Antifungal Combination Therapy and Surgical Approach for Aspergillus fumigatus Suppurative Thyroiditis Associated with Thyrotoxicosis and Review of Published Reports
2017-01-01 Nicole', Stefano; Lanzafame, Massimiliano; Cazzadori, Angelo Antonio; Vincenzi, Marcello; Mangani, Francesca; Colato, Chiara; EL DALATI, Ghassan; Brazzarola, Paolo; Concia, Ercole
VIROLOGICAL EFFICACY OF A REDUCED DOSE OF NEVIRAPINE IN A SMALL COHORT OF SUPPRESSED HIV-1-INFECTED PATIENTS
2015-01-01 Lanzafame, M; Lattuada, E; Cucchetto, G; Nicolè, S; Concia, Ercole; Vento, S.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials | 1-gen-2018 | Nicole', Stefano; Lanzafame, M; Cucchetto, Giulia; Rigo, F; Lattuada, E; Concia, E | |
| Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient | 1-gen-2017 | Lanzafame, Massimiliano; Lattuada, Emanuela; Nicole', Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro | |
| Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load <100 000 copies/mL: a medium-term follow-up | 1-gen-2017 | Lanzafame, Massimiliano; Nicole', Stefano; Gibellini, Davide; Lattuada, Emanuela; Cucchetto, Giulia; Rigo, Fabio; Diani, Erica; Concia, Ercole; Vento, Sandro | |
| Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients | 1-gen-2017 | Rigo, F; Cucchetto, G; Lanzafame, Massimiliano; Nicolè, S; Lattuada, Emanuela; Concia, Ercole; Vento, Sandro | |
| Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients | 1-gen-2019 | Nicolè, Stefano; Lanzafame, Massimiliano; Lattuada, Emanuela; Luise, Dora; Vecchi, Marta; Tacconelli, Evelina; Vento, Sandro | |
| Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study | 1-gen-2019 | Rizzardo, Sebastiano; Lanzafame, Massimiliano; Lattuada, Emanuela; Bragantini, Damiano; Nicolè, Stefano; Calza, Leonardo; Tacconelli, Evelina | |
| Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir | 1-gen-2018 | Lanzafame, M; Nicole, S; Rizzardo, S; Piacentini, D; Chiesi, S; Lattuada, E; Diani, E; Carelli, M; Vento, S; Gibellini, D | |
| Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings | 1-gen-2017 | Cucchetto, Giulia; Lanzafame, Massimiliano; Nicolè, Stefano; Lattuada, Emanuela; Calza, Leonardo; Concia, Ercole | |
| Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients | 1-gen-2015 | Lanzafame, Massimiliano; Lattuada, Emanuela; Rigo, Fabio; Nicole, Stefano; Cucchetto, Giulia; Vento, Sandro | |
| Successful Antifungal Combination Therapy and Surgical Approach for Aspergillus fumigatus Suppurative Thyroiditis Associated with Thyrotoxicosis and Review of Published Reports | 1-gen-2017 | Nicole', Stefano; Lanzafame, Massimiliano; Cazzadori, Angelo Antonio; Vincenzi, Marcello; Mangani, Francesca; Colato, Chiara; EL DALATI, Ghassan; Brazzarola, Paolo; Concia, Ercole | |
| VIROLOGICAL EFFICACY OF A REDUCED DOSE OF NEVIRAPINE IN A SMALL COHORT OF SUPPRESSED HIV-1-INFECTED PATIENTS | 1-gen-2015 | Lanzafame, M; Lattuada, E; Cucchetto, G; Nicolè, S; Concia, Ercole; Vento, S. |